Foventa Therapeutics

Foventa Therapeutics is a clinical-stage biotechnology company dedicated to preserving

sight through the development of innovative ophthalmic medicines. Our lead programme,

FOV407, is being developed as a topical eye drop for non-proliferative diabetic retinopathy

(NPDR), a common complication of diabetes that can lead to irreversible vision loss. Unlike

current treatments that are typically reserved for later stages of disease and require

injections into the eye, FOV407 is designed to offer a non-invasive approach that could

enable earlier intervention and greater patient convenience. Built on years of research into

retinal biology, angiogenesis and vascular leakage, Foventa combines scientific innovation

with a patient-first mindset.

For more information, visit Foventa.com

• Eye Health